01:35 PM EDT, 10/15/2025 (MT Newswires) -- Abbott Laboratories' ( ABT ) third-quarter sales fell short of Wall Street's forecasts as diagnostics revenue dropped, while the healthcare company narrowed its full-year profit guidance.

Sales rose 6.9% year-over-year to $11.37 billion for the September quarter, missing the FactSet-polled consensus of $11.39 billion. Adjusted earnings climbed to $1.30 per share from $1.21 a year earlier, in line with the Street's expectation.

Revenue within Abbott's diagnostics division declined 6.6% to $2.25 billion in the third quarter, below analysts' $2.28 billion view, with US sales falling 14%.

The company's stock dropped 4.9% during Wednesday trading.

"As expected, challenging market conditions in China impacting both price and volume remain a headwind for our core lab diagnostic business," Chief Executive Robert Ford said during an earnings call, according to a FactSet transcript. "Excluding China, core lab diagnostics grew 7% with markets such as the US showing an acceleration in growth in the third quarter compared to growth in the first half of this year."

The company is now expecting 2025 adjusted earnings of between $5.12 and $5.18 per share, compared with $5.10 to $5.20 previously expected. Analysts polled by FactSet are looking for $5.15, compared with last year's $4.67.

Abbot continues to expect full-year organic sales growth of 7.5% to 8%, excluding COVID-19 testing-related sales.

Nutrition revenue rose 4.2% to $2.15 billion in the third quarter, but fell short of the $2.21 billion consensus. Medical devices surged nearly 15% to $5.45 billion, while established pharmaceuticals' sales jumped 7.5%.

Price: 127.21, Change: -5.47, Percent Change: -4.12